

KEY  
WORDS  
OF MODERN  
ANTIFUNGAL  
THERAPY

# CYTOCHROME P450

## OR WHAT'S IN A NAME...

The metabolism of fungi is almost identical to that of other eukaryotic organisms, such as humans. Therefore, trying to design a systemic drug that kills fungi without harming their human host means searching for infinitesimal differences in metabolic pathways.

**Selective precision** for the metabolic pathways in fungi, as distinct from those in humans, remains the key determinant for any systemic antimycotic, regardless of its point of biochemical interaction. This precision has been achieved to an exceptional degree with itraconazole, alias Sporanox\*, because it selectively inactivates the fungal cytochrome P450 only.

Figure 1 is a simplified illustration of one of the pathways for the enzymatic ergosterol synthesis in fungal cell membranes. (Ergosterol is essential for the structural cohesion of these membranes). Pharmacologically one can disrupt this process at two distinct points. The first is where squalene is made into an oxide. Alternatively, one can interfere where lanosterol is converted into ergosterol, by inactivating **cytochrome P450** — a chemical catalyst that performs a vital function in the enzymatic reaction. The broadest research experience to date has been gathered with the latter approach. Importantly, in view of the close similarities between the enzymatic processes in fungi and humans, either approach must be highly selective in disrupting the fungal enzyme systems only.

**Sporanox** \*  
itraconazole

## SHORT AND SIMPLE ORAL THERAPY

standard dose in dermatomycoses: 1 capsule (100 mg) once daily for 15 days  
standard dose in vaginal candidosis: 2 x 2 capsules (400 mg) for 1 day only

\* Trademarks: SPORANOX, SEMPERA, SISTIZOL, TRISPORAL.

**JANSSEN**  
PHARMACEUTICA  
2340 Beerse, Belgium  
expertise in  
antimycotic research

**Properties:** Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, fungal keratitis and oral candidosis. **Dosage and administration:** Vulvovaginal candidosis: 2 capsules (200 mg) morning and evening for 1 day, Pi-

tyriasis versicolor: 2 capsules (200 mg) once daily for 7 days. - Tinea corporis, tinea cruris, tinea pedis, tinea manus: 1 capsule (100 mg) daily for 15 days; highly keratinized regions, as in plantar tinea pedis and palmar tinea manus, require 1 capsule (100 mg) daily for 30 days. - Oral candidosis: 1 capsule (100 mg) daily for 15 days. - Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole) is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanax (itraconazole) has not been associated with hepatotoxicity, it is advisable not to give this drug to patients with a known history of liver disease. Patients should be recommended not to breast feed while taking Sporanax (itraconazole). **Drug interactions:** Sporanax (itraconazole) should be given cautiously with warfarin.

zole) has not been associated with hepatotoxicity, it is advisable not to give this drug to patients with a known history of liver disease. Patients should be recommended not to breast feed while taking Sporanax (itraconazole). **Drug interactions:** Sporanax (itraconazole) should be given cautiously with warfarin.

SEND FOR YOUR  
FREE SAMPLE COPY

# Journal of Medical Genetics

EDITOR: PETER S HARPER

North American Editor: P. Michael Conneally • Cytogenetics Editor: Patricia A. Jacobs  
Molecular Genetics Editor: Kay E. Davies • Reviews Editor: Rodney Harris

## JOURNAL OF MEDICAL GENETICS

the first to be devoted specifically to medical genetics, is pleased to announce continuing developments, in response to the needs of readers and authors.

The journal will continue to feature General Reviews, Syndrome of the Month, Conference Reports, Original Papers and Short Reports on all aspects of medical genetics.

## RESEARCH AREAS OF SPECIAL EMPHASIS

### NEW FEATURES FOR 1992

- Half Price Personal Subscriptions for all Members of Major Societies, including European Society for Human Genetics and Clinical Genetics Society
- Change to A4 Format – providing
  - Improved Illustration Quality
  - Faster Publication
- New Literature Update Section
- New Gene Mapping Review Series on Major Chromosomal Regions
- Colour Reproduction

- Molecular Genetics and its Clinical and Cytogenetic Applications
- Dysmorphology and the Detection of New Syndromes
- Fundamental Aspects of Human Genetics
- Development of Clinical Genetic Services

1991 Subscription Prices: UK & Euro: £125  
Overseas: \$135 (USA: \$230)

To Order Your Subscription or Sample Copy Please Complete the Order Form Below

**Order Form**

JOURNAL OF MEDICAL GENETICS

0952-2593

Subscription: Monthly

Subscription Rate: £125 (USA: \$230)

Please tick: ☐ Personal ☐ Institutional

Please send me a ☐ Sample Copy ☐ Full Subscription

Please send me a ☐ Check ☐ Credit Card

(Payable to British Medical Association)

I wish to pay by ☐ Cheque ☐ Credit Card

Imprint: Exp. Date: Delete as appropriate)

Send orders to: BMA House, Tavistock Square, London WC1H 9JP

Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

Postcode: \_\_\_\_\_

Country: \_\_\_\_\_

Telephone: \_\_\_\_\_

Signature: \_\_\_\_\_



# gastric distress & oesophagitis hyperacidity or dysmotility?

Most complaints of gastric distress, as well as oesophagitis, are conventionally attributed to hyperacidity in the stomach. However, the contemporary view in gastroenterology holds that most upper G.I. problems, including heartburn, postprandial fullness, early satiety, abdominal distension and epigastric discomfort, are commonly motility related.<sup>1-3</sup> And this stands to reason. After all, proper peristalsis is a physiological necessity for our digestive process.


Prepulsid, the novel G.I. prokinetic, uniquely restores healthy peristalsis to efficiently clear the oesophagus and empty the stomach.<sup>4,6</sup>

**Prepulsid**  
CISAPRIDE

restores upper G.I. motility like no other agent.

**JANSSEN**  
PHARMACEUTICA  
B-2340 Beerse, Belgium

expertise in digestive motility



References: 1. Kuo, J.E. et al. Dig. Dis. Sci. 29: 183-184 (1984); 2. Kivilius, J.P. et al. Gastroenterology 91: 897 (1986); 3. Malagelada, J.R. et al. Gastroenterology 88: 1223 (1985); 4. Caccari, P. et al. Hepato-Gastroenterol. 34: 113 (1987); 5. Collins, B.J. et al. Hepato-Gastroenterol. 34: 113 (1987); 6. Jan, R. et al. Dig. Dis. Sci. 34: 657 (1989).

Prescribing information - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. Therapeutic indications: 1. Gastroesophageal reflux disorders, including oesophagitis. 2. Symptoms of X-ray or endoscopic negative upper digestive discomfort. 3. Gastroesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. Contraindications: No absolute contraindications are known. Precautions: Pregnancy: Although there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. Nursing mothers: Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. Driving and machine-operating ability: Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. Interactions: The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs: absorption of drugs from the stomach may be diminished, whereas absorption of drugs from the small bowel may be accelerated (e.g. benzocaine, anticholinergics, anticonvulsants, paracetamol). The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonistic to those of anticholinergic drugs. In the elderly, elderly patients may require individual titration. It may be useful to monitor plasma levels of such drugs when Prepulsid is associated. Adverse reactions: In line with its prokinetic effect, Prepulsid may cause diarrhoea, which is usually mild and self-limiting. In the elderly, elderly patients may require individual titration. There have been isolated reports of convulsive seizures without clearcut relationship to Prepulsid. Dosage: Adults: according to the severity of the condition, 5 or 10 mg of Prepulsid, 2 to 4 times daily, to be taken as tablets or as oral suspension (the full plastic 5 ml spoon contains 5 mg). As a rule the following doses have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. \* severe conditions (gastroesophageal reflux, oesophagitis, refractory constipation): 10 mg t.i.d. (before the 3 main meals and before retiring). \* infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension, intakes are indicated on the dosing pipet as a function of body weight. Full prescribing information available on request.

Note: Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.